Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Details

vida: extract claims from 2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026

- Source: inbox/queue/2026-05-05-fda-oral-wegovy-approval-oasis4-jan2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-05 04:18:27 +00:00

1.7 KiB

Raw Blame History

type	entity_type	name	parent_company	status	domain
entity	protocol	Wegovy Oral (Oral Semaglutide)	Novo Nordisk	FDA approved	health

Wegovy Oral (Oral Semaglutide)

Type: GLP-1 receptor agonist, oral formulation
Manufacturer: Novo Nordisk
Status: FDA approved January 2026
Indication: Weight management in adults with obesity or overweight + ≥1 comorbidity; cardiovascular risk reduction in adults with CVD + obesity/overweight

Overview

First oral GLP-1 receptor agonist approved for weight management. Eliminates injection barrier that limited injectable semaglutide (Wegovy) adoption.

Clinical Evidence

OASIS 4 Trial (Phase III):

Duration: 64 weeks
Population: n=307
Primary endpoint: Weight loss 16.6% (treatment) vs 2.7% (placebo) with reduced calorie diet + exercise
Safety: Serious adverse events 3.9% (treatment) vs 8.8% (placebo)
Common adverse reactions: nausea, vomiting, diarrhea (standard GLP-1 class profile)

Regulatory Status

FDA Label (January 2026):

Boxed warning: Thyroid C-cell tumor risk (standard GLP-1 class warning)
NO eating disorder warning or screening requirement
Suicidal behavior/ideation warning REMOVED in 2026 review (no causal link found)
No contraindications for psychiatric comorbidity or eating disorder history

Market Significance

Oral formulation expands addressable GLP-1 population by eliminating injection barrier. Accelerates trajectory toward mass-market adoption (1-in-8 Americans forecast).

Manufacturing

Novo Nordisk North Carolina facilities.

Timeline

2026-01-01 — FDA approval for weight management and cardiovascular risk reduction
2026-01-01 — Launch with North Carolina manufacturing capacity

1.7 KiB Raw Blame History